Huemer, Florian http://orcid.org/0000-0001-9184-4038
Weiss, Lukas
Faber, Viktoria
Neureiter, Daniel
Egle, Alexander
Geissler, Klaus
Voskova, Daniela
Zebisch, Armin
Burgstaller, Sonja
Pichler, Angelika
Stauder, Reinhard
Sperr, Wolfgang
Lang, Alois
Pfeilstöcker, Michael
Machherndl-Spandl, Sigrid
Stampfl, Margarete
Greil, Richard
Pleyer, Lisa
Funding for this research was provided by:
Austrian Registry on Hypomethylating Agents - Arbeitsgemeinschaft Medikamentöse Tumortherapie
Paracelsus Medical University
Article History
Received: 7 September 2017
Accepted: 6 January 2018
First Online: 30 January 2018
Compliance with ethical guidelines
:
: F. Huemer received travel support from Roche and Merck. L. Weiss reports receiving honoraria from Bayer, Ipsen, Lilly and Shire; travel support from Abbvie, BMS, Pfizer and Pharmamar; research funding from Takeda. A. Egle is a consultant for Celgene and reports receiving honoraria from Celgene. K. Geissler has been a member of advisory boards for Celgene. A. Zebisch reports receiving honoraria from Celgene and Novartis. S. Burgstaller has been a consultant for Celgene and Novartis, a member on the Board of Directors or advisory committees for Celgene and Novartis and reports receiving research funding from Celgene and honoraria from AOP Orphan Pharmaceuticals, Celgene, Mundipharma and Novartis. R. Stauder has been a consultant and a member on the Board of Directors or advisory committees for Celgene and reports receiving research funding and honoraria from Celgene, Teva (Ratiopharm) and Novartis. W.R. Sperr has been a consultant for Celgene. Alois Lang has been a consultant for Celgene. M. Pfeilstöcker has been a consultant for Celgene and Novartis and reports receiving honoraria from Celgene, Novartis and Janssen-Cilag. S. Machherndl-Spandl has been a member of an advisory board for Celgene. R. Greil reports receiving honoraria from Bristol-Myers-Squibb, Cephalon, Amgen, Eisai, Mundipharma, Merck, Janssen-Cilag, Genentech, Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Roche and Sanofi Aventis, research funding from Cephalon, Celgene, Amgen, Mundipharma, Genentech, Pfizer, GSK and Ratiopharm and has been a consultant for Bristol-Myers-Squibb, Cephalon and Celgene. L. Pleyer has been a consultant for Agios, Celgene, Bristol-Myers Squibb and Novartis and reports receiving honoraria and travel support from Agios, Celgene, Bristol-Myers Squibb, Novartis and AOP Orphan Pharmaceuticals. V. Faber, D. Neureiter, D. Voskova, A. Pichler, M. Stampfl declare that no competing interests exist.
: This retrospective analysis was approved by the Ethics Committee of the provincial government of Salzburg, Austria (reference number 415-EP/39/11). All patients alive at the time point of data acquisition signed an informed consent to allow the collection of personal data.